Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL.
Related Questions
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
In an elderly transplant ineligible IDH1-mutated patient with AML, who is in remission after 6 cycles of azacitidine and ivosidenib, would you discontinue azacitidine after cycle 6 and continue maintenance ivosidenib until progression/toxicity or continue both azacitidine and ivosidenib?
Do you add venetoclax +/- anti CD-20 mAb to a BTKi in patients with CLL who no longer wish to remain on a BTKi many months after starting the BTKi?
Does treating CLL reduce the risk of non-melanoma skin cancers?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?
In treatment naive patients with del 17p/TP53 negative CLL, will the recent interim analysis of fixed duration acalabrutinib plus venetoclax +/- obinutuzumab vs chemoimmunotherapy in the AMPLIFY trial (published in the NEJM) change your practice?
